157 related articles for article (PubMed ID: 37313946)
21. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
Ananthakrishnan AN; Sakuraba A; Barnes EL; Pekow J; Raffals L; Long MD; Sandler RS
Aliment Pharmacol Ther; 2017 Jul; 46(2):162-168. PubMed ID: 28470787
[TBL] [Abstract][Full Text] [Related]
22. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
[TBL] [Abstract][Full Text] [Related]
25. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
26. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
27. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
28. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
29. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
30. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
Bouhnik Y; Atreya R; Casey D; Górecki M; Baik D; Yoon SW; Kwon TS; Jang M
Inflamm Bowel Dis; 2023 Jun; 29(6):898-913. PubMed ID: 35942647
[TBL] [Abstract][Full Text] [Related]
32. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
33. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.
Taxonera C; Olivares D; Mendoza JL; Díaz-Rubio M; Rey E
World J Gastroenterol; 2014 Jul; 20(27):9170-7. PubMed ID: 25083091
[TBL] [Abstract][Full Text] [Related]
34. PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
Martinez-Vinson C; Lemoine A; Bouhnik Y; Braithwaite B; Fohlen-Weill A; Addison J
J Pediatr Gastroenterol Nutr; 2023 Apr; 76(4):451-459. PubMed ID: 36729422
[TBL] [Abstract][Full Text] [Related]
35. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
36. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of clinical characteristics and drug treatment of inflammatory bowel disease in children: a single center study].
Zhang R; Zhong XM; Gong YZ; Ma X; Zhu D; Ning HJ; Wang FP; Zou JZ; Zhang YL
Zhonghua Er Ke Za Zhi; 2020 Jul; 58(7):570-575. PubMed ID: 32605341
[No Abstract] [Full Text] [Related]
38. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
40. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
